Urinary tract infections (UTIs) are the second most common nosocomial infections caused by bacteria of Enterobacteriaceae family. Along the urinary tract these bacterial infections can occur anywhere in kidneys, ureters and bladder of both men and women but predominantly in women leading to morbidity and mortality. Current therapies available to treat UTI are use of either antibiotics alone or in combination of two antibiotics and inhibitors from plant derived products with antibiotics. However treatment of these combinations failed to kill the bacteria completely as most of the bacteria develop resistance to available therapies. In present invention formulation contain three potentiators and one antibiotic which increase the bactericidal efficacy of β-lactam antibiotics. The formulation contain three potentiators such as Kaempferol, Ellagic acid. Gallic acid .Caffeine, Theobromine and Theophylline etc. along with at least one β-lactam antibiotic like Cefotaxime, Ceftriaxone, Ceftazidime, Cefepime and Penicillin etc. The antibiotics and potentiators are easily available in the market. The formulation is effective against highly drug resistant UTI bacteria viz. Enterobacter cancerogenus MAB-1, Escherichia furgusonii GCR-1, Shigella flexnerii SMB-1 and Spingomonas paucimobilis to the extent of 98-99% in 2-5 hrs. The formulation is an effective treatment in the management of UTI, cost effective, short-term therapy and anti-inflammatory in nature.
